Here's why you should add PacBio stock to your portfolio now
This article argues for adding PacBio stock to an investment portfolio.
Pacific Biosciences of California traces DNA sequencing evolution from Sanger to HiFi platforms
Pacific Biosciences of California (PacBio) is advancing DNA sequencing from traditional Sanger methods to its powerful HiFi long-read platforms. The company emphasizes the rapid evolution within genomics, urging scientists to embrace new innovations for more accurate and comprehensive genetic analysis. PacBio's HiFi technology offers detailed insights into cancer variation and allows mapping of structural variants and novel isoforms in cancer genomics on a single platform, enhancing both research and clinical applications.
Pacific Biosciences (NASDAQ: PACB) officer sells 88,185 shares for taxes
James R. Gibson II, an officer at Pacific Biosciences (NASDAQ: PACB), reported an open-market sale of 88,185 shares at a weighted average price of $1.37 per share. These shares were mandatorily sold to cover tax withholding obligations linked to the vesting of restricted stock units. After this transaction, Gibson still directly holds 1,245,663 shares of common stock.
Pacific Biosciences of California Inc expected to post a loss of 13 cents a share - Earnings Preview
Pacific Biosciences of California Inc (PACB) is projected to report a loss of 13 cents per share. This financial forecast comes from Refinitiv as part of an earnings preview. The article provides a brief overview of the expected performance for the company.
Powering cancer testing research with HiFi whole genome sequencing and targeted panels
The article discusses how HiFi whole genome sequencing (WGS) and targeted panels are advancing cancer testing research. It highlights that HiFi technology provides accurate multiomic sequencing, offering a more complete view of the cancer genome, transcriptome, and epigenome, which is crucial for detecting complex variants often missed by standard approaches. The piece also details how partnerships with industry leaders like Agilent and QIAGEN extend the capabilities of HiFi sequencing for comprehensive genomic profiling and hereditary cancer risk assessment.
[144] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing
This article details a Form 144 SEC filing by Pacific Biosciences of California, Inc. (PACB) for a proposed sale of securities. The filing indicates the sale of 88,185 common shares acquired as restricted stock on March 31, 2026, through Morgan Stanley Smith Barney LLC. The article provides the market value, outstanding shares, and emphasizes the filer's representation that they are unaware of any material adverse, undisclosed information concerning the issuer.
Here’s Why PacBio Shares Deserve a Place in Your Portfolio Today
PacBio (PACB) is highlighted as a strong buy due to its innovative sequencing technology, expanding product portfolio with Revio and Vega systems, and consistent financial performance that has exceeded expectations. Despite challenges with extended sales cycles and academic funding limitations, analyst estimates for 2026 show improving sentiment, with projected revenue growth and a narrowed loss per share. The company's leadership in the growing SMRT technology market and strategic collaborations further position it for future success.
Powered by PacBio: Selected publications from January – March 2026
This article showcases selected research publications from January to March 2026, highlighting the diverse applications of PacBio HiFi sequencing in areas like rare disease, cancer, and transcriptomics. It details how the technology is revealing new insights into ALS transcript biology, enabling advanced machine learning in cancer research, and improving diagnostics for rare genetic disorders through comprehensive genomic and transcriptomic analysis. The studies demonstrate the advantages of long-read sequencing in capturing complex genetic variations and full-length transcripts that short-read methods often miss.
Pacific Biosciences of California unveils oncology workflow solutions at industry event
Pacific Biosciences of California is presenting its HiFi sequencing technology and Vega system at the AACR26 conference in San Diego. The company aims to showcase how its solutions can enhance oncology workflows and provide comprehensive insights into cancer biology with high accuracy. This demonstration builds on previous advancements in HiFi sequencing for detailed cancer variation analysis and automated epigenetic data detection.
PACB PE Ratio & Valuation, Is PACB Overvalued
This article analyzes the valuation of Pacific Biosciences of California Inc (PACB), suggesting it is currently in the "Fair zone" with a forward PS ratio of 3.24. It provides a fair price range between $0.88 and $8.71 based on relative valuation. However, it also notes that PACB's P/B ratio is significantly higher than its historical averages and its P/S ratio, while below competitors, still appears unsustainable given its revenue growth.
Pacific Biosciences Stock: Long-Read Sequencing Leader Faces Evolving Genomics Landscape
Pacific Biosciences (PacBio) is a leader in long-read DNA sequencing technology, positioning itself centrally in the expanding genomics sector with its Revio and Onso systems. The company's technology offers high accuracy for complex genomic analysis, crucial for applications in human genomics, infectious diseases, and plant breeding. While operating in a competitive market, PacBio maintains its edge through technological innovation, strategic partnerships, and recurring revenue from consumables, appealing to North American investors interested in U.S.-centric biotech innovation.
Pacific Biosciences of California (PACB) registers a bigger fall than the market: Important facts to note
This article analyzes why Pacific Biosciences of California (PACB) experienced a more significant market decline, highlighting key financial and operational details that may have contributed to its underperformance compared to the broader market. It suggests that investors should consider specific factors influencing PACB's stock.
PacBio (PACB) Q2 Earnings Report Preview: What To Look For
This article provides a preview of PacBio's upcoming Q2 earnings report, highlighting key metrics and expectations. Investors are anticipating robust revenue growth and an update on the company's financial performance. The report will be crucial for assessing PacBio's market position and future outlook in the genomics sector.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) reported a narrower-than-expected loss in its second quarter, although it still posted a non-GAAP diluted net loss per share of $0.23. The company successfully beat revenue estimates, recording $38.03 million against an expected $34.79 million. Despite this revenue beat, the firm's stock has seen a significant year-to-date decline.
Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider
Pacific Biosciences of California (PACB) recently experienced a significant stock price drop, falling 6.67% to $1.26 while the broader market saw smaller declines. Over the past month, PACB's stock decreased 24.16%, outpacing the Medical sector's 7.36% and the S&P 500's 6.15% losses. Despite this, the company holds a Zacks Rank of #1 (Strong Buy) within the Medical – Instruments industry, with analysts anticipating a 10.36% increase in revenue for the upcoming quarter, despite a projected 13.33% decline in EPS.
Vanguard amendment shows 0 PACB shares after realignment (PACB)
The Vanguard Group filed an amendment to its Schedule 13G/A for Pacific Biosciences of California Inc (PACB), reporting 0 shares beneficially owned as of March 13, 2026. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately. The filing confirms that The Vanguard Group no longer holds beneficial ownership over these securities.
Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider
Pacific Biosciences of California (PACB) recently saw its stock price drop by 6.67% to $1.26, underperforming major market indices like the S&P 500, Dow Jones, and Nasdaq. Over the last month, PACB's stock has declined by 24.16%, significantly more than its sector average. Despite negative earnings per share projections for the upcoming report, analysts anticipate revenue growth, and the company currently holds a Zacks Rank of #1 (Strong Buy).
Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider
Pacific Biosciences of California (PACB) stock recently fell by 6.67% to $1.26, underperforming major indices and the Medical sector. Analysts are anticipating a 13.33% decline in EPS for the upcoming quarter, despite a projected 10.36% increase in revenue. Despite recent declines, PACB currently holds a Zacks Rank of #1 (Strong Buy) within the Medical - Instruments industry, signaling potential for future growth based on analyst confidence.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) reported a narrower-than-expected loss in its Q2 earnings, with a loss of $0.30 per share which was better than the Zacks Consensus Estimate of a $0.33 loss. The company also surpassed revenue estimates, posting $38.35 million against an anticipated $37.07 million. Despite beating estimates, the revenue figure represents a slight year-over-year decline.
PacBio Secures Agreement with Basecamp Research for Trillion Gene Atlas Project
PacBio has partnered with Basecamp Research for the ambitious Trillion Gene Atlas project, utilizing its HiFi sequencing on the Revio platform to create the largest and most diverse high-fidelity metagenomic dataset. This collaboration aims to advance AI-powered drug discovery by providing comprehensive genomic information for Basecamp's EDEN platform, speeding up the creation of new therapies. The agreement is expected to drive demand for PacBio's technology and consumables, with the company currently holding a Zacks Rank #1 (Strong Buy) and the long-read sequencing market projected for significant growth.
Pacific Biosciences of California grants early SPRQ-Nx beta access to scientists for HiFi sequencing
Pacific Biosciences of California has given early beta access to its SPRQ-Nx sequencing chemistry to a select group of scientists, including Katy Munson from the University of Washington. This program allows experts to evaluate the new technology's workflow and economic benefits, which is designed to enhance high-fidelity sequencing. The company previously launched HiFi sequencing for cancer research and automatic epigenetic detection through HiFi sequencing runs.
2025 Immunology and Immunotherapy SMRT Grant winners announced
PacBio and ClareoBio have announced the four winners of the 2025 PacBio Immunology and Immunotherapy SMRT Grant. The grant attracted hundreds of proposals from researchers globally, all aiming to use ClareoBio's ProfilAIR assay powered by PacBio HiFi sequencing for advanced immune profiling. The selected projects will explore B-cell receptor repertoires in Kawasaki disease, IgG subclass dynamics in Chronic Lymphocytic Leukemia, clonal dynamics in DLBCL patients undergoing CAR-T therapy, and maternal-infant immune profiling following vaccination.
Pacific Biosciences of California researcher uncovers genetic variants shaping brain disorders
Pacific Biosciences of California is exploring the genetic basis of rare ataxias to understand neurological function and disorders better. By focusing on small communities, the company's research aims to identify subtle genetic variants and population patterns to advance personalized medicine and neurological research. This initiative builds on their recent developments in HiFi sequencing technology for detailed cancer variation analysis and automatic epigenetic detection.
Pacific Biosciences of California (PACB) dips more than broader market: What you should know
This article from MSN provides a concise financial update on Pacific Biosciences of California (PACB). It notes that PACB's stock underperformed the broader market, as indicated by its trading dip. Investors seeking quick summaries of market performance would find this information relevant.
Pacific Biosciences of California (PACB) Falls Further Than the Overall Market: Key Information to Note
Pacific Biosciences of California (PACB) stock recently dropped 5% to $1.33, underperforming the broader market and the Medical sector over the past month. Investors are awaiting its next earnings report, where analysts project a loss of $0.17 per share and a revenue increase to $41 million. Despite recent declines, PACB currently holds a Zacks Rank of #2 (Buy), indicating potential for future outperformance within the Medical - Instruments industry.
Pacific Biosciences of California expands cancer research with new epigenetics lesson in sequencing series
Pacific Biosciences of California has launched a new epigenetics lesson as part of its Cancer Sequencing 101 series. This video explains how researchers can use HiFi sequencing data to analyze DNA methylation and chromatin accessibility for cancer discovery. The educational initiative aims to equip scientists and clinicians with essential knowledge to foster innovation in oncology research.
Cancer genomics myths revisited: How advances in HiFi sequencing keep strengthening the evidence
This article debunks common misconceptions about long-read sequencing in cancer genomics, highlighting how HiFi sequencing advances are making it more affordable, compatible with FFPE samples, and effective for detecting complex transcriptomic dysregulation and somatic variants. It emphasizes the improving throughput and bioinformatics accessibility of HiFi sequencing, along with its increasing clinical utility in research.
DNA Sequencing Market size to hit $108.95 Billion by 2035 | Top
The DNA Sequencing Market is projected to reach $108.95 billion by 2035, growing at a CAGR of 20.5% from its 2025 valuation of USD 16.88 billion. This growth is driven by advancements in Next-Generation Sequencing (NGS) technologies, increasing applications in precision medicine, and the integration of AI and bioinformatics. Key players like Illumina, Thermo Fisher Scientific, and Pacific Biosciences are innovating to expand their market presence.
Canaccord reiterates Pacific Biosciences stock rating on new chemistry
Canaccord Genuity has reiterated a "Buy" rating and a $3.00 price target for Pacific Biosciences of California (NASDAQ:PACB), anticipating growth from its new SPRQ-Nx chemistry and reusable SMRT cells expected in late 2026. This technology aims to improve data yield and reduce costs, positioning the company for larger-scale sequencing applications despite near-term macro and funding challenges. However, the company faces financial headwinds, including a "WEAK" financial health score, and while recent earnings exceeded expectations, Barclays downgraded the stock due to a lack of immediate catalysts.
Pacific Biosciences (PACB) upgraded to strong buy: What does it mean for the stock?
This article announces that Pacific Biosciences (PACB) has been upgraded to a "strong buy" rating. It will likely discuss the implications of this upgrade for the company's stock performance. Investors and potential investors will be interested in understanding the factors driving this upgraded rating and its potential impact on PACB's market position.
Pacific Biosciences (PACB) Raised to Strong Buy: What Are the Implications for Its Shares?
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy) due to positive shifts in its earnings outlook and improved earnings projections. This rating, based on objective earnings revisions, suggests a favorable earnings trajectory and potential for the stock's outperformance, as Zacks Rank #1 stocks have historically shown strong returns. The company is projected to report earnings of -$0.54 per share for fiscal year 2026, with recent analyst estimates for PACB increasing by 5.3%.
Inside the trillion-gene atlas training AI to design new medicines
PacBio (NASDAQ: PACB) has announced a collaboration with Basecamp Research to power the Trillion Gene Atlas using PacBio HiFi sequencing on the Revio system with SPRQ-Nx chemistry. This initiative aims to generate approximately 100,000 deeply sequenced samples from 31 countries across 5 continents, creating the largest high-fidelity metagenomic dataset to date. The goal is to leverage this expansive and diverse data to train next-generation AI models for biological design and accelerate the development of transformative medicines.
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock?
Pacific Biosciences of California (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates. The Zacks rating system highlights companies with improving earnings outlooks, which often correlate with near-term stock price movements. This upgrade places PACB in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns.
Pacific Biosciences of California Q2 2025 Earnings Preview
This article provides a preview of Pacific Biosciences of California's Q2 2025 earnings. It likely discusses expectations for the company's financial performance in the upcoming quarter.
Pacific Biosciences of California introduces HiFi sequencing for comprehensive cancer analysis
Pacific Biosciences of California is advancing cancer analysis with its HiFi sequencing technology, designed to detect a full range of cancer variations including structural variants, methylation patterns, RNA isoforms, and fusions. This single platform aims to provide comprehensive genomic insights, positioning PacBio as a key player in oncology research. The company has also emphasized its previous work on integrating automatic epigenetic detection within HiFi sequencing, further enhancing its ability to deliver deeper and more accurate genomic data for cancer studies.
PACB,TAL Options
This article provides detailed financial and news information for Pacific Biosciences of California Inc (PACB) and TAL Education Group (TAL). It includes stock performance metrics, insider trading activities, analyst ratings, and recent news headlines for both companies, offering a comprehensive overview for potential investors.
Pacific Biosciences of California technology maps cancer structural variants in single platform advance
Pacific Biosciences of California has unveiled new research showcasing its PacBio HiFi technology, which can map hundreds of structural variants, novel isoforms, and critical fusions in cancer genomics. This advanced platform aims to predict patient survival and guide treatment by providing comprehensive genetic insights through a single workflow. This innovation has the potential to significantly impact cancer research and clinical applications and builds upon earlier advancements in epigenetic detection.
HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts
Pacific Biosciences of California has introduced its HiFi sequencing platform, which can automatically detect epigenetic modifications like 5-methylcytosine (5mC) and 6-methyladenine (6mA) in a single sequencing run. This technology uses kinetic signature analysis, eliminating the need for extra library preparation. The company highlights its efficiency for genomic researchers by providing simultaneous sequence and epigenetic information.
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB)
Pacific Biosciences of California (NASDAQ:PACB) currently trades at $1.33 USD, up 4.72% today, but has seen significant declines over longer periods. ChartMill assigns PACB a technical rating of 0/10 and a fundamental rating of 2/10, citing poor profitability and financial health. Analysts, however, forecast an average price target of $2.48, suggesting an 86.25% increase, with expected EPS growth of 71.86% and revenue growth of 10.42% in the next year.
AI biotech leader Chris Gibson joins PacBio (PACB) board of directors
PacBio (NASDAQ: PACB) has appointed Christopher Gibson, Ph.D., co-founder and Chairman of Recursion, to its Board of Directors as a Class I director, effective March 3, 2026. This appointment expands the board to ten members, with Dr. Gibson also serving on the Science and Technology Committee. His expertise in leveraging AI, automation, and high-dimensional biological data for drug discovery aligns with PacBio's strategic vision of integrating HiFi long-read sequencing with advanced analytics to unlock biological insights.
[Form 4] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Insider Trading Activity
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) director Christopher Gibson reported equity awards stemming from his election to the Board on March 3, 2026. He received stock options for 73,087 shares and a grant of 53,913 restricted stock units (RSUs). These awards, not open-market purchases, vest over several years contingent on his continued service as a director, with the first vesting dates in March 2027.
Patent deal locks in protections for Pacific Biosciences (NASDAQ: PACB) with PGI
Pacific Biosciences (NASDAQ: PACB) has settled a patent dispute with Personal Genomics of Taiwan, Inc. (PGI), securing a worldwide, royalty-free, non-exclusive license and a five-and-a-half-year covenant not to sue from PGI. In exchange, PacBio will make fixed payments totaling $8 million in Q1 2026 and $5 million in Q1 2027, 2028, and 2029, with potential increases to the 2027 payment based on 2026 revenue. Additionally, Pacific Biosciences announced the voluntary resignation of its Chief Accounting Officer, Michele Farmer, with CFO Jim R. Gibson assuming her responsibilities.
PACB - Pacific Biosciences of California Inc Stock Price and Quote
The article provides a detailed overview of Pacific Biosciences of California Inc (PACB) stock, including its latest trading information, financial metrics, and recent news. It highlights the company's stock performance, insider transactions, and a list of analyst ratings, alongside recent operational and financial announcements.
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
PacBio has appointed Christopher Gibson, Ph.D., co-founder and Chairman of Recursion, to its Board of Directors. Dr. Gibson's expertise in leveraging AI, automation, and high-dimensional biological data for scientific discovery is expected to strengthen PacBio's efforts in integrating sequencing, computation, and data-driven discovery to maximize the power of HiFi sequencing. This strategic move aims to accelerate understanding and treatment of complex diseases by combining advanced sequencing technologies with AI-driven analytics.
Pacific Biosciences announces accounting officer transition and litigation settlement
Pacific Biosciences of California (NASDAQ:PACB) announced that Chief Accounting Officer Michele Farmer will resign on March 21, with CFO Jim R. Gibson assuming her responsibilities. The company also settled litigation with Personal Genomics of Taiwan through a licensing agreement and a payment schedule totaling at least $18 million. These developments follow recent news of better-than-expected Q4 2025 financial results but a stock downgrade by Barclays, and the appointment of Christopher Gibson to its Board of Directors.
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know
Shares of PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes fell after a February jobs report indicated an unexpected contraction in employment, particularly in the healthcare sector. This news raised investor concerns about a potential economic slowdown and reduced healthcare spending. The article also touches on PacBio's stock volatility, recent dips due to inflation concerns, and its significant year-to-date decline.
PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News
Barclays has downgraded Pacific Biosciences (PACB) from an Equal-Weight to an Underweight rating, simultaneously reducing its price target by 25% from $2.00 to $1.50. This adjustment follows several rating changes from other analysts in late 2025, which primarily maintained neutral or overweight ratings with various price targets. Despite the downgrade, the average one-year price target from 7 analysts suggests a potential upside of 59.77% from the current price, and the brokerage firm consensus indicates an "Outperform" status for PACB.
Barclays downgrades Pacific Biosciences stock rating on catalysts
Barclays downgraded Pacific Biosciences of California (NASDAQ:PACB) from Equalweight to Underweight, setting a price target of $1.50 due to a lack of meaningful near-term upside despite acknowledging the company's technology and management. The firm highlighted concerns about Pacific Biosciences' rapid cash burn, significant debt, and the illiquidity of its stock, forecasting underperformance relative to its peers. This downgrade comes despite recent positive financial results and a new board appointment for Pacific Biosciences.
PacBio Appoints New Board Member
PacBio has appointed Dr. Christopher Gibson, co-founder of Recursion, to its Board of Directors, leveraging his expertise in AI-driven drug discovery to enhance its genomic strategies. Dr. Gibson's experience in integrating large-scale biological data with machine learning aligns with PacBio's goals for data-driven discovery and accelerating clinical development. This appointment is expected to strengthen PacBio's market competitiveness and accelerate healthcare discoveries through AI analytics combined with its long-read sequencing technology.
Beyond the Bench: Exploring the terrain of repeat expansion diseases with HiFi sequencing
This article highlights Dr. Birgitt Schuele's research on repeat expansion diseases, particularly Spinocerebellar Ataxia Type 10 (SCA10), using PacBio's HiFi sequencing technology. It explains how HiFi sequencing overcomes the limitations of short-read methods by providing long, accurate reads to precisely characterize complex repeat regions, which is crucial for understanding and developing treatments for these neurological disorders. The article emphasizes the blend of personal passion and technological innovation driving advancements in genomics.
